Clinical Trial

Neoadjuvant Treatment For Locally Advanced Thymic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations for the establishment of unified evaluation criteria for the neoadjuvant therapy of thymic cancer by evaluating the pathological remission status of thymic cancer specimens after neoadjuvant treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-30; most recent amendment 2026-05-05.
Trial Details
NCT Number NCT06019468
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Conditions Thymic Carcinoma
Enrollment 25 participants
Start Date 2023-11-04
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-08